Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Anebulo Pharmaceuticals Inc

Healthcare US ANEB

0.3751USD
-0.0256(6.39%)

Last update at 2026-06-03T19:47:00Z

Day Range

0.380.44
LowHigh

52 Week Range

0.303.42
LowHigh

Fundamentals

  • Previous Close 0.40
  • Market Cap20.39M
  • Volume9380
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.18

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-12-31 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-12-31 2022-06-30
Income before tax -8.48476M -8.20200M -11.73234M -6.82562M -6.82562M
Minority interest - - - - -
Net income -8.48476M -8.20200M -11.73234M -6.82562M -6.82562M
Selling general administrative 4.92M 4.75M 6.18M 3.87M 3.87M
Selling and marketing expenses - 0.00480M - - -
Gross profit - - - - -
Reconciled depreciation - - - - -
Ebit - -8.05000M -11.78360M -11.78360M -6.82545M
Ebitda -8.10275M -7.79172M -11.78360M -6.81829M -6.82562M
Depreciation and amortization - 0.26M 0.01M - 6.83M
Non operating income net other - - - - -
Operating income -9.22348M -8.30900M -11.78360M -6.83117M -6.83117M
Other operating expenses 9.22M 8.31M 11.78M 6.83M 6.83M
Interest expense 0.38M 0.15M 0.00000M 0.00733M 0.00733M
Tax provision - - - - -
Interest income 0.26M 0.25M 0.15M 0.09M 0.09M
Net interest income -0.12410M 0.10M 0.15M 0.09M 0.09M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - -0.10419M - -0.01289M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 9.22M 8.31M 11.78M 6.83M 6.83M
Cost of revenue - - - - -
Total other income expense net 0.74M 0.11M -0.04115M 0.00556M 0.00556M
Discontinued operations - - - - -
Net income from continuing ops -8.48476M -8.20170M -11.60133M -11.73234M -11.73234M
Net income applicable to common shares - - - -11.73234M -11.73234M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-12-31 2023-06-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-12-31 2023-06-30 2022-12-31
Total assets 12.15M 4.07M 11.67M 11.67M 15.58M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.26M 0.41M 0.42M 0.42M 1.03M
Total liab 0.49M 0.26M 1.07M 1.07M 0.51M
Total stockholder equity 11.66M 3.81M 10.60M 10.60M 15.07M
Deferred long term liab - - - - -
Other current liab - 0.10M - 0.53M 0.13M
Common stock 0.04M 0.03M 0.03M 0.03M 0.02M
Capital stock 0.04M 0.03M - 0.03M 0.03M
Retained earnings -73.88851M -65.40374M -57.20204M -57.20204M -45.46970M
Other liab - - - - -
Good will - - - - -
Other assets - - 0.42M 0.42M -
Cash 11.63M 3.09M 11.25M 11.25M 14.55M
Cash and equivalents - - - - -
Total current liabilities 0.22M 0.26M 0.53M 1.07M 0.51M
Current deferred revenue - - - - -
Net debt -11.62785M -3.09420M -11.24740M -11.24740M -14.54847M
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - - -
Other stockholder equity 85.51M 69.19M 67.78M 67.78M 60.51M
Property plant equipment - - - - -
Total current assets 11.96M 3.51M 11.25M 11.67M 15.58M
Long term investments - - - - -
Net tangible assets - - - - 10.60M
Short term investments - - - - -
Net receivables 0.07M - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.22M 0.16M 0.53M 0.53M 0.38M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - 0.00000M 0.00000M -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.18M 0.57M - - -
Deferred long term asset charges - - - - -
Non current assets total 0.18M 0.57M - 0.00000M 0.00000M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-12-31 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-12-31 2022-06-30
Investments - - - - -
Change to liabilities - - - 0.15M 0.15M
Total cashflows from investing activities - - - - -
Net borrowings - - - - 0.00000M
Total cash from financing activities 14.88M -0.06235M 6.38M 6.38M 6.38M
Change to operating activities - - - 1.01M 1.01M
Net income -8.48476M -8.20170M -11.73234M -6.82562M -6.82562M
Change in cash 8.53M -8.15320M -3.30107M -5.43717M -5.43717M
Begin period cash flow 3.09M 11.25M 14.55M 19.99M 19.99M
End period cash flow 11.63M 3.09M 11.25M 14.55M 14.55M
Total cash from operating activities -6.34969M -8.09085M -9.68313M -5.43717M -5.43717M
Issuance of capital stock 15.00M 0.00000M 6.65M 6.65M 6.65M
Depreciation 0.38M 0.15M - - -
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.07322M - - - -
Sale purchase of stock - - - - -
Other cashflows from financing activities 14.88M -0.06235M -0.26468M -0.31708M -0.31708M
Change to netincome - - - 0.88M 0.88M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.31M -0.79926M 1.16M 0.91M 0.91M
Stock based compensation 1.45M 0.76M 0.88M 0.48M 0.48M
Other non cash items 0.31M 0.15M 0.73M - 0.48M
Free cash flow -6.34969M -8.09085M -9.68313M -5.43717M -5.43717M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
ANEB
Anebulo Pharmaceuticals Inc		 -0.0256 6.39% 0.38 - - - 2.57 -6.5351
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.

Anebulo Pharmaceuticals Inc

1017 Ranch Road 620 South, Lakeway, TX, United States, 78734

Key Executives

Name Title Year Born
Dr. Joseph F. Lawler M.D., Ph.D. Founder & Chairman 1972
Mr. Simon J. Allen B.Sc., M.B.A., MBA CEO & Director 1968
Mr. Rex Merchant CFA CFO & Sec. 1960
Dr. Kenneth C. Cundy Ph.D. Chief Scientific Officer 1959
Mr. Scott L. Anderson Head of Investor Relations & Public Affairs NA
Mr. Richard Anthony Cunningham CEO & Director 1971
Mr. Daniel V. George Principal Accounting Officer, Acting CFO & Secretary 1970
Mr. Daniel V. George Acting CFO & Secretary 1970

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions